BSE Live
Apr 07, 16:01Prev. Close
336.95
Open Price
337.10
Bid Price (Qty.)
338.50 (6)
Offer Price (Qty.)
339.70 (50)
NSE Live
Apr 07, 15:56Prev. Close
336.90
Open Price
336.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
339.20 (99)
| Cash Flow of FDC (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 367.67 | 397.95 | 265.69 | 285.45 | 380.45 | |
| Net CashFlow From Operating Activities | 310.34 | 220.81 | 164.72 | 162.38 | 209.84 | |
| Net Cash Used In Investing Activities | -199.45 | -17.76 | 3.62 | -147.42 | -84.18 | |
| Net Cash Used From Financing Activities | -92.10 | -202.03 | -179.83 | -9.70 | -126.49 | |
| Foreign Exchange Gains / Losses | 0.12 | 0.01 | 0.11 | 0.15 | 0.02 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 18.90 | 1.02 | -11.38 | 5.41 | -0.80 | |
| Cash And Cash Equivalents Begin of Year | 20.77 | 19.75 | 31.13 | 25.72 | 26.52 | |
| Cash And Cash Equivalents End Of Year | 39.67 | 20.77 | 19.75 | 31.13 | 25.72 |
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
10.02.2026
FDC Consolidated December 2025 Net Sales at Rs 464.71 crore, up 0.13% Y-o-Y
09.02.2026
FDC Standalone December 2025 Net Sales at Rs 457.94 crore, down 0.2% Y-o-Y
11.11.2025
FDC Standalone September 2025 Net Sales at Rs 461.74 crore, down 8.58% Y-o-Y
07.11.2025
FDC Consolidated September 2025 Net Sales at Rs 473.03 crore, down 7.94% Y-o-Y
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
07.04.2026
07.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth